PTCT
PTC Therapeutics Inc
62.70$
+0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 4.8% | 34.6% | 7.0% | 8.3% | 5.5% | 7.6% | 1.1% | 6.4% | 54.9% | 9.9% | 10.3% | 5.5% | 17.9% | |
| 95.2% | 65.4% | 93.0% | 91.7% | 94.5% | 92.4% | 98.9% | 93.6% | 45.1% | 90.1% | 89.7% | 94.5% | 82.1% | |
| 83.5% | 39.5% | 55.3% | 70.8% | 82.0% | 58.5% | 9.3% | 63.2% | 47.5% | 80.8% | 37.0% | 27.5% | 43.0% | |
| 41.1% | 26.3% | 34.9% | 37.2% | 37.3% | 39.7% | 6.9% | 47.7% | 39.8% | 58.8% | 31.6% | 22.4% | 34.5% | |
| 155.3% | 64.4% | 114.6% | 113.2% | 122.2% | 168.5% | 16.4% | 113.2% | 43.6% | 139.7% | 72.9% | 53.2% | 70.6% | |
| -60.1% | 1.0% | -21.6% | -21.5% | -27.7% | -76.2% | 82.5% | -19.5% | 1.4% | -49.6% | 16.8% | 41.3% | 11.5% | |
| 14.3% | 14.4% | 19.4% | 23.3% | 21.1% | 19.3% | 2.9% | 17.0% | 15.4% | 33.5% | 18.0% | 13.4% | 18.4% | |
| -84.7% | -51.1% | -40.3% | -45.9% | -49.8% | -44.4% | 79.1% | -39.7% | -10.9% | -84.5% | -0.9% | 27.1% | -6.6% | |
| -17.1% | -0.4% | 3.3% | 7.2% | 4.4% | -13.5% | 5.4% | -3.5% | -18.5% | -2.5% | 0.1% | 3.9% | -2.8% | |
| -67.6% | -50.7% | -43.6% | -53.1% | -54.2% | -30.9% | 73.7% | -36.3% | 7.5% | -82.0% | -1.0% | 23.2% | -3.8% | |
| -37.6% | -10.4% | 5.5% | -18.9% | -25.4% | -22.0% | 82.6% | -18.5% | 9.8% | -43.1% | 22.7% | 44.9% | 17.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.